# @blackstone on Instagram

- **Type:** Video
- **Original URL:** https://www.instagram.com/p/C0P2_vzP0LZ
- **Gondola URL:** https://gondola.cc/posts/76421572-blackstone-instagram
- **Thumbnail:** https://img.gondola.cc/tr:w-,h-,fo-auto/postThumbnails/7167a61e45.jpg
- **Posted:** 2023-11-29T23:11:13.000+00:00
- **Account Owner:** Blackstone (@blackstone) — https://gondola.cc/blackstone

## Caption

Our portfolio company Anthos Theraputics announced groundbreaking trial data for their anti #bloodclot 🩸 treatment, abelacimab, at the American_Heart Conference — a 67% reduction in bleeding compared to a current standard of care. Hear more from StopTheClot and #Blackstone leaders. 👆🔊

The treatment also reduced the risk of potentially life-threatening major bleeding events by 74% and gastrointestinal bleeding by 93%. That makes abelacimab a potential game-changer for patients at risk of #strokes and #heartattacks.

We’re thrilled to back Anthos and this promising new treatment. Learn more about our long-term partnership with Anthos and why we’re so excited about this latest milestone at the link in our bio. 🔗

## Stats

- **Views:** 0
- **Likes:** 97
- **Shares:** 0
- **Comments:** 0

## Credits

No public credits are recorded here. This does not identify who made the post.

## Tags

bloodclot, strokes, blackstone, heartattacks

---
Copyright (c) Gondola